We're sorry but this page doesn't work properly without JavaScript enabled. Please enable it to continue.
Feedback

Brain glycoprotein glycosylation in health and disease

Formale Metadaten

Titel
Brain glycoprotein glycosylation in health and disease
Serientitel
Anzahl der Teile
31
Autor
Mitwirkende
Lizenz
CC-Namensnennung 4.0 International:
Sie dürfen das Werk bzw. den Inhalt zu jedem legalen Zweck nutzen, verändern und in unveränderter oder veränderter Form vervielfältigen, verbreiten und öffentlich zugänglich machen, sofern Sie den Namen des Autors/Rechteinhabers in der von ihm festgelegten Weise nennen.
Identifikatoren
Herausgeber
Erscheinungsjahr
Sprache
Produzent
Produktionsjahr2022
ProduktionsortFrankfurt am Main

Inhaltliche Metadaten

Fachgebiet
Genre
Abstract
The brain contains a multitude of glycoproteins modified with glycans on multiple amino acids, including N-glycans and O-glycans, but the functions and structures of the glycans and all sites of glycosylation on proteins is not yet well defined. Our analyses are revealing that the assortment of the major N-glycans in the brain glycoproteins of mice and humans have a remarkable enrichment of relatively small-sized glycans, including pauci- and oligomannose, hybrid-type, and complex-type lacking extensive galactosylation or sialylation, despite the overall repertoire of glycans being relatively robust. All of these results are consistent with transcriptomic analyses of murine and human brains. Many human psychiatric and brain disorders, including schizophrenia and Alzheimer’s Disease (AD) may be linked to changes in protein glycosylation. In our studies on schizophrenia, we have focused on a missense mutation (A391T) in SLC39A8, encoding a manganese-transporter, that is strongly associated with schizophrenia in genomic studies, though the molecular connection to the brain is unknown. We have investigated brain glycosylation in a knock-in mouse model homozygous for A391T, and found that there are significant changes in protein N-glycosylation in the brain, also associated with changes in glycoprotein expression. In Alzheimer’s disease patients, along with brain samples from asymptomatic and normal controls, we have analyzed the overall glycoproteome, identifying many hundreds of different glycoproteins and sites of glycosylation, and identified significant changes in N-glycosylation patterns that differ from normal and asymptomatics. Our studies are revealing mechanistic links between a risk allele and potentially reversible biochemical changes in the schizophrenic brain, furthering our molecular understanding of the pathophysiology of schizophrenia and a novel opportunity for therapeutic development. Also, the new information on brain glycoproteome in AD may provide new biomarkers of disease and effects of modern therapeutic interventions.
Schlagwörter